Yaq-001 在肝硬化模型与患者中的临床、实验及病理生理效应:一种非吸收性肠道限制性吸附剂
本研究在体外、两种大鼠肝硬化与慢加急性肝衰竭模型、两种小鼠肝硬化模型中评估非吸收性肠道限制性工程碳珠吸附剂 Yaq-001,并开展多中心双盲随机安慰剂对照临床试验,28 例肝硬化患者接受 4 克/天 Yaq-001 治疗 3 个月。Yaq-001 快速吸附内毒素,在动物中显著减轻肝损伤、纤维化进展、门静脉高压、肾功能障碍及慢加急性肝衰竭死亡率,临床试验达到安全性与耐受性主要终点。
要点
- Yaq-001 为口服非吸收性肠道限制性吸附剂,体外显示对內毒素具有快速吸附动力学。
- 动物模型中 Yaq-001 显著降低肝损伤、纤维化进展、门静脉高压、肾功能障碍及慢加急性肝衰竭死亡率。
- 28 例肝硬化患者 4 克/天治疗 3 个月的多中心双盲随机安慰剂对照试验达到安全性与耐受性主要终点。
核心结论
- 本研究为 Yaq-001 提供了较强的临床前依据,并显示其在肝硬化患者中的安全性,支持临床转化。
研究设计与样本
- 体外评估 Yaq-001 性能;采用两种大鼠肝硬化与慢加急性肝衰竭模型(4 周胆管结扎伴或不伴脂多糖,Yaq-001 干预 2 周)及两种小鼠肝硬化模型(6 周和 12 周四氯化碳,Yaq-001 干预 6 周)。
- 分析器官与免疫功能、肠道通透性、转录组学、微生物组组成及代谢组学;并用动物模型粪水在肠道类器官上评估肠道通透性。
- 开展多中心、双盲、随机、安慰剂对照临床试验,28 例肝硬化患者接受 Yaq-001 4 克/天治疗 3 个月。
主要发现
- Yaq-001 表现出对內毒素的快速吸附动力学。
- 在体内,Yaq-001 显著降低慢加急性肝衰竭动物的肝损伤、纤维化进展、门静脉高压、肾功能障碍及死亡率。
- 观察到对內毒素血症严重程度、高氨血症、肝细胞死亡、全身炎症及器官转录组学的显著影响,肝、肾、脑和结肠中炎症、细胞死亡与衰老呈可变调节。
- Yaq-001 降低类器官肠道通透性,并对微生物组组成与代谢产生积极影响。
- Yaq-001 作为器械管理,在临床试验中达到安全性与耐受性主要终点。
关键数值与推荐
- 临床试验中 Yaq-001 剂量为 4 克/天,疗程 3 个月,受试者为 28 例肝硬化患者。
- Yaq-001 作为器械管理,主要终点为安全性与耐受性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Targeting bacterial translocation in cirrhosis is limited to antibiotics with risk of antimicrobial resistance. This study explored the therapeutic potential of a non-absorbable, gut-restricted, engineered carbon bead adsorbent, Yaq-001 in models of cirrhosis and acute-on-chronic liver failure (ACLF) and, its safety and tolerability in a clinical trial in cirrhosis. DESIGN: Performance of Yaq-001 was evaluated in vitro. Two-rat models of cirrhosis and ACLF, (4 weeks, bile duct ligation with or without lipopolysaccharide), receiving Yaq-001 for 2 weeks; and two-mouse models of cirrhosis (6-week and 12-week carbon tetrachloride (CCl4)) receiving Yaq-001 for 6 weeks were studied. Organ and immune function, gut permeability, transcriptomics, microbiome composition and metabolomics were analysed. The effect of faecal water on gut permeability from animal models was evaluated on intestinal organoids. A multicentre, double-blind, randomised, placebo-controlled clinical trial in 28 patients with cirrhosis, administered 4 gr/day Yaq-001 for 3 months was performed. RESULTS: Yaq-001 exhibited rapid adsorption kinetics for endotoxin. In vivo, Yaq-001 reduced liver injury, progression of fibrosis, portal hypertension, renal dysfunction and mortality of ACLF animals significantly. Significant impact on severity of endotoxaemia, hyperammonaemia, liver cell death, systemic inflammation and organ transcriptomics with variable modulation of inflammation, cell death and senescence in the liver, kidneys, brain and colon was observed. Yaq-001 reduced gut permeability in the organoids and impacted positively on the microbiome composition and metabolism. Yaq-001 regulated as a device met its primary endpoint of safety and tolerability in the clinical trial. CONCLUSIONS: This study provides strong preclinical rationale and safety in patients with cirrhosis to allow clinical translation. TRIAL REGISTRATION NUMBER: NCT03202498.
引用
- Liu J, MacNaughtan J, Kerbert AJC, et al. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis. Gut. 2024. PMID: 38621924. doi:10.1136/gutjnl-2023-330699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。